The company Libytec PHARMACEUTICAL S.A. was founded in June 2008 with the aim of offering reliable proposals of modern pharmaceutical formulations to the health sector. It represents a modern approach in the field of Health, meeting contemporary demands and boasting a valuable portfolio of medicines across multiple therapeutic categories.
Today, Libytec launches a innovative dermocosmetic product for the treatment of hair loss, CG 210.
As you know, severe hair loss in men and women is caused by different factors, and while it may seem insignificant to others, it often has a significant emotional impact on those affected.
In many cases, severe hair loss, regardless of the cause, is due to a disruption of the normal hair growth cycle.
CG210 is aimed at men and women dealing with hair loss. The worldwide and innovative mechanism of action of CG210 is distinguished in three parts:
The result is that, provided there are healthy hair follicles and the product is used regularly, hair loss returns to normal in less than 44 days ensuring high levels of satisfaction.
The action of CG 210 is due to the significant increase in BCL-2 levels and their restoration close to normal values. This is a protein considered a key regulator of apoptosis. At the same time, the amount of collagen around hair follicles increases, reducing the diameter of the pores, thus facilitating better hair implantation and minimizing contact with external infectious agents.
Regarding product safety, test results show that CG 210 is non-irritating, hypoallergenic, and does not cause skin intolerance. Furthermore, the product is non-oily, contains no preservatives, dyes, or glycerol, has a low alcohol content, and a low fragrance concentration.
CG 210 is a combination of active ingredients with clinically proven efficacy in hair growth and hair loss. Each box contains 80ml of topical solution in foam form for external use. The product is available in different packaging for men and women. Each box also includes a pump.
The main ingredients are:
The product is marketed internationally under the same name CG 210, a research product of the Swiss company Legacy, and is manufactured in France.
CG210 was selected by Nikkei Health magazine as the recommended product for the treatment of hair loss in Japan.
It is available in major European countries (such as France, Spain, Italy, Belgium) since the end of 2013 under the brand name Oenobiol by Sanofi. In France, during the first month of the product's launch, the average number of new users was 1,000 per week.
In Southeast Asia, it has been available since October 2014 under the brand name CG 210 by Abbott Laboratories.
In Australia, Switzerland, Russia, Japan, Canada, China, Brazil, South Africa, Mexico, Argentina, Venezuela, Colombia, India, Korea, and the Philippines, its distribution is handled by Galderma pharmaceutical under the brand name CG 210.
